479 related articles for article (PubMed ID: 18035676)
21. Molecular genetic changes in epithelial, stromal and mixed neoplasms of the endometrium.
Lax SF
Pathology; 2007 Feb; 39(1):46-54. PubMed ID: 17365822
[TBL] [Abstract][Full Text] [Related]
22. A multistep model for ovarian tumorigenesis: the value of mutation analysis in the KRAS and BRAF genes.
Russell SE; McCluggage WG
J Pathol; 2004 Jun; 203(2):617-9. PubMed ID: 15141374
[TBL] [Abstract][Full Text] [Related]
23. Molecular carcinogenesis of endometrial cancer.
Liu FS
Taiwan J Obstet Gynecol; 2007 Mar; 46(1):26-32. PubMed ID: 17389185
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical characterization of mullerian mucinous borderline tumors: possible histogenetic link with serous borderline tumors and low-grade endometrioid tumors.
Yasunaga M; Ohishi Y; Oda Y; Misumi M; Iwasa A; Kurihara S; Nishimura I; Okuma E; Kobayashi H; Wake N; Tsuneyoshi M
Hum Pathol; 2009 Jul; 40(7):965-74. PubMed ID: 19269675
[TBL] [Abstract][Full Text] [Related]
25. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis.
Dehari R; Kurman RJ; Logani S; Shih IeM
Am J Surg Pathol; 2007 Jul; 31(7):1007-12. PubMed ID: 17592266
[TBL] [Abstract][Full Text] [Related]
26. Histologic type, organ of origin, and Wnt pathway status: effect on gene expression in ovarian and uterine carcinomas.
Shedden KA; Kshirsagar MP; Schwartz DR; Wu R; Yu H; Misek DE; Hanash S; Katabuchi H; Ellenson LH; Fearon ER; Cho KR
Clin Cancer Res; 2005 Mar; 11(6):2123-31. PubMed ID: 15788657
[TBL] [Abstract][Full Text] [Related]
27. New insights on the pathogenesis of ovarian carcinoma: molecular basis and clinical implications.
Gadducci A; Guerrieri ME; Genazzani AR
Gynecol Endocrinol; 2012 Aug; 28(8):582-6. PubMed ID: 22304686
[TBL] [Abstract][Full Text] [Related]
28. Molecular genetic alterations in endometrioid carcinomas of the ovary: similar frequency of beta-catenin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomas.
Catasús L; Bussaglia E; Rodrguez I; Gallardo A; Pons C; Irving JA; Prat J
Hum Pathol; 2004 Nov; 35(11):1360-8. PubMed ID: 15668893
[TBL] [Abstract][Full Text] [Related]
29. Frameshift mutations in the bax gene are not involved in development of ovarian endometrioid carcinoma.
Cao SN; Chang KH; Luthra R; Liu J
Mod Pathol; 2003 Oct; 16(10):1048-52. PubMed ID: 14559989
[TBL] [Abstract][Full Text] [Related]
30. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways.
Wu R; Hendrix-Lucas N; Kuick R; Zhai Y; Schwartz DR; Akyol A; Hanash S; Misek DE; Katabuchi H; Williams BO; Fearon ER; Cho KR
Cancer Cell; 2007 Apr; 11(4):321-33. PubMed ID: 17418409
[TBL] [Abstract][Full Text] [Related]
31. Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma.
Salvador S; Rempel A; Soslow RA; Gilks B; Huntsman D; Miller D
Gynecol Oncol; 2008 Sep; 110(3):408-17. PubMed ID: 18597838
[TBL] [Abstract][Full Text] [Related]
32. Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplasms in patients 50 years of age and younger.
Jensen KC; Mariappan MR; Putcha GV; Husain A; Chun N; Ford JM; Schrijver I; Longacre TA
Am J Surg Pathol; 2008 Jul; 32(7):1029-37. PubMed ID: 18469706
[TBL] [Abstract][Full Text] [Related]
33. Oviductal glycoprotein, a new differentiation-based indicator present in early ovarian epithelial neoplasia and cortical inclusion cysts.
Woo MM; Gilks CB; Verhage HG; Longacre TA; Leung PC; Auersperg N
Gynecol Oncol; 2004 May; 93(2):315-9. PubMed ID: 15099939
[TBL] [Abstract][Full Text] [Related]
34. Histological classification of ovarian cancer.
Kaku T; Ogawa S; Kawano Y; Ohishi Y; Kobayashi H; Hirakawa T; Nakano H
Med Electron Microsc; 2003 Mar; 36(1):9-17. PubMed ID: 12658347
[TBL] [Abstract][Full Text] [Related]
35. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis.
Shih IeM; Kurman RJ
Am J Pathol; 2004 May; 164(5):1511-8. PubMed ID: 15111296
[TBL] [Abstract][Full Text] [Related]
36. Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas.
Wiegand KC; Lee AF; Al-Agha OM; Chow C; Kalloger SE; Scott DW; Steidl C; Wiseman SM; Gascoyne RD; Gilks B; Huntsman DG
J Pathol; 2011 Jul; 224(3):328-33. PubMed ID: 21590771
[TBL] [Abstract][Full Text] [Related]
37. [Dualistic model of molecular pathogenesis in endometrial carcinoma].
Lax SF
Zentralbl Gynakol; 2002 Jan; 124(1):10-6. PubMed ID: 11873308
[TBL] [Abstract][Full Text] [Related]
38. Subdividing ovarian and peritoneal serous carcinoma into moderately differentiated and poorly differentiated does not have biologic validity based on molecular genetic and in vitro drug resistance data.
Vang R; Shih IeM; Salani R; Sugar E; Ayhan A; Kurman RJ
Am J Surg Pathol; 2008 Nov; 32(11):1667-74. PubMed ID: 18769340
[TBL] [Abstract][Full Text] [Related]
39. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.
Bonome T; Lee JY; Park DC; Radonovich M; Pise-Masison C; Brady J; Gardner GJ; Hao K; Wong WH; Barrett JC; Lu KH; Sood AK; Gershenson DM; Mok SC; Birrer MJ
Cancer Res; 2005 Nov; 65(22):10602-12. PubMed ID: 16288054
[TBL] [Abstract][Full Text] [Related]
40. High-grade ovarian serous carcinoma exhibits significantly higher p16 expression than low-grade serous carcinoma and serous borderline tumour.
O'Neill CJ; McBride HA; Connolly LE; Deavers MT; Malpica A; McCluggage WG
Histopathology; 2007 May; 50(6):773-9. PubMed ID: 17493241
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]